Using CalmiGo to Manage Anxiety and Panic Attack Symptoms in the Emergency Department
Key facts
- Who runs it
- Yves Duroseau
- Where
- Manhattan, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 35 people enrolled
- Started
- 7 Aug 2019
- Ended
- 4 Dec 2024
- Type of study
- Interventional
- Treatments tested
- CalmiGo
- Record updated
- 14 April 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Patients in the LHH Emergency Department (ED)
- Presenting with anxiety and panic attack symptoms (confirmed by ED provider)
- Able to provide informed consent
- Must be aged 18 years or older
Who cannot take part
- Chief obstructive pulmonary disorder (COPD)
- Bi-polar disorder
- Psychosis or delusional disorders
- History of substance abuse or dependence
- History of being suicidal
- Organic mental disorder
- Severe unstable medical illness
- Chronic respiratory disease
- History of seizures
- Patients less than 18 years of age
- Pregnant patients
- Prisoners
- Cognitively impaired
- Asthma
Where in United States
- Lenox Hill HospitalManhattan, United States
About the trial
What the trial wants to find out
Currently, there are limited options in the management of anxiety and panic attack symptoms in the Emergency Department (ED). The most common treatment method is the use of anti-anxiety and anti-depressant medications; however, these drugs have serious health risks which make them ineffective as a long-term treatment option. The CalmiGo handheld device, formerly known as "myReLeaf", provides an alternative early intervention option in treating patients presenting with anxiety and panic attack symptoms by using guided breathing, aromatherapy, and grounding techniques. The hypothesis of this study is that CalmiGo will provide a drug-free, early intervention, and long-term treatment option in the ED that will improve patients' anxiety and panic attack symptoms.
Read full original descriptionShow less
Patients who present to the ED with anxiety or panic attack symptoms will be considered eligible for this study. These patients will be approached, and they will give informed consent to participate in the study. Patients will be enrolled in the study which consists of completing validated surveys asking about their anxiety and panic symptoms, using CalmiGo, and allowing investigators to access their medical records. These surveys will be completed before and after using CalmiGo in the ED to measure the presence and severity of anxiety and panic symptoms. The goal of this study is to analyze the effectiveness of using CalmiGo to improve anxiety and panic attack symptoms based on validated survey responses.
Overall, this study seeks to identify CalmiGo as an effective and alternative early intervention treatment option for patients presenting to the ED with anxiety or panic attack symptoms.
The group in the trial
- CalmiGo RecipientsTreatment being tested
This arm will receive a CalmiGo handheld device during their participation in the study. Participants will first complete validated surveys assessing their anxiety and panic attack symptoms. Investigators will then demonstrate how to use the CalmiGo handheld device. Participants will use the device with the investigator and then participants will use the device on their own for at least 2 times. After using CalmiGo, participants will complete validated surveys reassessing their anxiety and panic attack symptoms, asking about their past medical history, and inquiring about their experience using CalmiGo.
Treatment: CalmiGo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- The Use of the CalmiGo Handheld Device in the Management of Patients With Anxiety and Panic Attack Symptoms in the Emergency Department
- Record updated
- 14 April 2026